Arnatar Therapeutics has launched with $52M in VC funding to create a dual-modality RNA platform. Its first target is Alagille syndrome (ALGS). Arnatar Details Innovative Nucleic Acid drug development Chinese origin, founded in 2022 using $14.45M from Apricot Capital. Operated in Stealth mode until Series A in 2025 HQ in San Diego, CASource: CapitalIQ.com Series … Continue reading Arnatar Tx Launches with $52M in Series A funding